Is Unity Biotechnology Stock a Good Investment?
Unity Biotechnology Investment Advice | UBX |
- Examine Unity Biotechnology's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Unity Biotechnology's leadership team and their track record. Good management can help Unity Biotechnology navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Unity Biotechnology's business and its evolving consumer preferences.
- Compare Unity Biotechnology's performance and market position to its competitors. Analyze how Unity Biotechnology is positioned in terms of product offerings, innovation, and market share.
- Check if Unity Biotechnology pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Unity Biotechnology's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Unity Biotechnology stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Unity Biotechnology is a good investment.
Sell | Buy |
Cautious Hold
Market Performance | Very Weak | Details | |
Volatility | Relatively risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Unity Biotechnology Stock
Researching Unity Biotechnology's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 21.0% of the company outstanding shares are owned by institutional investors. The company has Price to Book (P/B) ratio of 1.36. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. Unity Biotechnology recorded a loss per share of 1.28. The entity had not issued any dividends in recent years. The firm had 1:10 split on the 20th of October 2022.
To determine if Unity Biotechnology is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Unity Biotechnology's research are outlined below:
| Unity Biotechnology generated a negative expected return over the last 90 days | |
| Unity Biotechnology may become a speculative penny stock | |
| Unity Biotechnology has a very high chance of going through financial distress in the upcoming years | |
| Reported Net Loss for the year was (39.86 M) with loss before taxes, overhead, and interest of (35.22 M). | |
| Unity Biotechnology has about 64.51 M in cash with (37.09 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.26, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Unity Biotechnology has a frail financial position based on the latest SEC disclosures | |
| Latest headline from gurufocus.com: Alyeska Investment Group L.P.s Strategic Acquisition in Unity Biotechnology Inc |
Unity Biotechnology Quarterly Liabilities And Stockholders Equity |
|
Unity Biotechnology uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Unity Biotechnology. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Unity Biotechnology's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 20th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 20th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Unity Biotechnology's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Unity Biotechnology's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-05-14 | 2024-03-31 | -0.48 | -0.34 | 0.14 | 29 | ||
2024-08-06 | 2024-06-30 | -0.46 | -0.31 | 0.15 | 32 | ||
2022-11-08 | 2022-09-30 | -1.65 | -1.36 | 0.29 | 17 | ||
2023-11-13 | 2023-09-30 | -0.96 | -0.66 | 0.3 | 31 | ||
2023-05-09 | 2023-03-31 | -1.08 | -0.76 | 0.32 | 29 | ||
2023-12-31 | 2023-12-31 | -0.8864 | -0.28 | 0.6064 | 68 | ||
2019-05-08 | 2019-03-31 | -5.07 | -4.4 | 0.67 | 13 | ||
2021-11-10 | 2021-09-30 | -3.71 | -3.0 | 0.71 | 19 |
Know Unity Biotechnology's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Unity Biotechnology is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Unity Biotechnology backward and forwards among themselves. Unity Biotechnology's institutional investor refers to the entity that pools money to purchase Unity Biotechnology's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Founders Fund V Management, Llc | 2024-06-30 | 49.2 K | Wells Fargo & Co | 2024-06-30 | 43.4 K | Cercano Management Llc | 2024-09-30 | 41.2 K | State Street Corp | 2024-06-30 | 37.8 K | Bridgeway Capital Management, Llc | 2024-09-30 | 25 K | Commonwealth Equity Services Inc | 2024-06-30 | 24.6 K | Northern Trust Corp | 2024-09-30 | 22.5 K | Susquehanna International Group, Llp | 2024-06-30 | 17.8 K | Endowment Wealth Management, Inc. | 2024-09-30 | 13.5 K | Arch Venture Corp | 2024-09-30 | 1 M | Alyeska Investment Group, L.p. | 2024-09-30 | 920 K |
Unity Biotechnology's market capitalization trends
The company currently falls under 'Micro-Cap' category with a total capitalization of 20.05 M.Market Cap |
|
Unity Biotechnology's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.61) | (0.64) | |
| Return On Capital Employed | (0.77) | (0.81) | |
| Return On Assets | (0.61) | (0.64) | |
| Return On Equity | (1.40) | (1.47) |
Determining Unity Biotechnology's profitability involves analyzing its financial statements and using various financial metrics to determine if Unity Biotechnology is a good buy. For example, gross profit margin measures Unity Biotechnology's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Unity Biotechnology's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Unity Biotechnology's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Unity Biotechnology. Check Unity Biotechnology's Beneish M Score to see the likelihood of Unity Biotechnology's management manipulating its earnings.
Evaluate Unity Biotechnology's management efficiency
Unity Biotechnology has Return on Asset of (0.3034) % which means that on every $100 spent on assets, it lost $0.3034. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.8695) %, meaning that it generated no profit with money invested by stockholders. Unity Biotechnology's management efficiency ratios could be used to measure how well Unity Biotechnology manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.64 in 2024. Return On Capital Employed is likely to drop to -0.81 in 2024. At this time, Unity Biotechnology's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 25.2 M in 2024, whereas Net Tangible Assets are likely to drop slightly above 57.5 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.92 | 1.83 | |
| Tangible Book Value Per Share | 1.92 | 1.83 | |
| Enterprise Value Over EBITDA | (0.96) | (1.01) | |
| Price Book Value Ratio | 1.00 | 1.07 | |
| Enterprise Value Multiple | (0.96) | (1.01) | |
| Price Fair Value | 1.00 | 1.07 | |
| Enterprise Value | 69.7 M | 66.2 M |
Unity Biotechnology's management has consistently demonstrated strong leadership, driving both financial growth and operational excellence. By analyzing current market trends and future growth opportunities, we assess the stock's true value and potential for investors.
Beta 0.827 |
Basic technical analysis of Unity Stock
As of the 27th of November, Unity Biotechnology has the Risk Adjusted Performance of (0.1), variance of 7.46, and Coefficient Of Variation of (713.70). In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Unity Biotechnology, as well as the relationship between them.Unity Biotechnology's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Unity Biotechnology insiders, such as employees or executives, is commonly permitted as long as it does not rely on Unity Biotechnology's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Unity Biotechnology insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Unity Biotechnology's Outstanding Corporate Bonds
Unity Biotechnology issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Unity Biotechnology uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Unity bonds can be classified according to their maturity, which is the date when Unity Biotechnology has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand Unity Biotechnology's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Unity Biotechnology's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.1) | |||
| Market Risk Adjusted Performance | (1.00) | |||
| Mean Deviation | 1.99 | |||
| Coefficient Of Variation | (713.70) | |||
| Standard Deviation | 2.73 | |||
| Variance | 7.46 | |||
| Information Ratio | (0.19) | |||
| Jensen Alpha | (0.44) | |||
| Total Risk Alpha | (0.82) | |||
| Treynor Ratio | (1.01) | |||
| Maximum Drawdown | 14.51 | |||
| Value At Risk | (4.11) | |||
| Potential Upside | 4.48 | |||
| Skewness | 1.01 | |||
| Kurtosis | 2.19 |
| Risk Adjusted Performance | (0.1) | |||
| Market Risk Adjusted Performance | (1.00) | |||
| Mean Deviation | 1.99 | |||
| Coefficient Of Variation | (713.70) | |||
| Standard Deviation | 2.73 | |||
| Variance | 7.46 | |||
| Information Ratio | (0.19) | |||
| Jensen Alpha | (0.44) | |||
| Total Risk Alpha | (0.82) | |||
| Treynor Ratio | (1.01) | |||
| Maximum Drawdown | 14.51 | |||
| Value At Risk | (4.11) | |||
| Potential Upside | 4.48 | |||
| Skewness | 1.01 | |||
| Kurtosis | 2.19 |
Consider Unity Biotechnology's intraday indicators
Unity Biotechnology intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Unity Biotechnology stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 2690.45 | |||
| Daily Balance Of Power | 0.4 | |||
| Rate Of Daily Change | 1.02 | |||
| Day Median Price | 1.19 | |||
| Day Typical Price | 1.2 | |||
| Price Action Indicator | 0.025 | |||
| Period Momentum Indicator | 0.02 |
Unity Stock media impact
Far too much social signal, news, headlines, and media speculation about Unity Biotechnology that are available to investors today. That information is available publicly through Unity media outlets and privately through word of mouth or via Unity internal channels. However, regardless of the origin, that massive amount of Unity data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Unity Biotechnology news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Unity Biotechnology relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Unity Biotechnology's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Unity Biotechnology alpha.
Unity Biotechnology Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Unity Biotechnology can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Unity Biotechnology Corporate Management
| Dr AB | CoFounder Director | Profile | |
| Nathan Guz | Vice Operations | Profile | |
| Judith Campisi | Founder | Profile | |
| Daohong MD | Founder | Profile | |
| Anirvan Ghosh | CEO Director | Profile | |
| Jamie MD | Chief Officer | Profile |
Additional Tools for Unity Stock Analysis
When running Unity Biotechnology's price analysis, check to measure Unity Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Unity Biotechnology is operating at the current time. Most of Unity Biotechnology's value examination focuses on studying past and present price action to predict the probability of Unity Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Unity Biotechnology's price. Additionally, you may evaluate how the addition of Unity Biotechnology to your portfolios can decrease your overall portfolio volatility.